Samjin Pharmaceutical launches oral anticoagulant 'Lexaban' ... targets edoxaban market

[Financial News] Samjin Pharmaceutical Co., Ltd. has launched a new oral anticoagulant and entered the edoxaban market. Its strategy is to strengthen its competitiveness in Korea’s anticoagulant market by leveraging its in-house production system and pricing the drug below the original product.
Samjin Pharmaceutical Co., Ltd.'s edoxaban-based oral anticoagulant tablets, Lexaban, in 15 mg, 30 mg and 60 mg strengths (Photo), were launched on the 11th, the company announced on the 12th.
Lexaban is a drug that prevents blood clots by directly inhibiting factor X (Factor Xa), which is involved in blood coagulation. It is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and to treat deep vein thrombosis and pulmonary embolism and reduce the risk of recurrence.
Samjin Pharmaceutical Co., Ltd. said it had secured supply stability by establishing an in-house production system covering everything from active pharmaceutical ingredients to finished drugs. For the 60 mg dose, the price was set about 56% below that of the original product. The tablet was also reduced to 10.6 mm in diameter to make it easier to take. Adults take it once a day, regardless of meals.
The launch also expands Samjin Pharmaceutical Co., Ltd.'s range of oral anticoagulants. With the addition of an edoxaban product to its existing apixaban-based Elsaban and rivaroxaban-based Riboxaban, the company now offers the major active ingredients in the factor Xa inhibitor class.
Samjin Pharmaceutical Co., Ltd. plans to expand its share of Korea’s edoxaban market, estimated to have annual prescription sales of about 120 billion won, by emphasizing supply stability and competitive pricing.

[email protected] Jung Sang-hee Reporter